Northern Antibiotics
Northern Antibiotics develops derivatives for the treatment of infections caused by resistant gram-negative bacteria.
Funding rounds
8/2013
Valuation after latest round
€5.5 million
Springvest's ownership stake
2.3% (31 December 2025)
Sector
Life sciences
